Effects of deep brain stimulation on cognitive functioning in treatment-resistant depression: a systematic review and meta-analysis

Runia, N.; Mol, G. J. J.; Hillenius, T.; Hassanzadeh, Z.; Denys, D. A. J. P.; Bergfeld, I. O.

doi:10.1038/s41380-023-02262-1

Cited by 3 publications

(1 citation statement)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, our findings hint that immediate and long-term modulation of glutamatergic and GABAergic neuron interplay may have driven long-term improvements in cognition that then related to remission-like performance in the GT. The translatability of this finding is supported by work in humans showing that mPFC DBS increases gamma activity (Scherer et al, 2023) and improves long-term measures of memory (Runia et al, 2023). Again, we must be cautious in overinterpreting these correlations, more work will need to be done to demonstrate causal links, if any.…”

Section: 13mentioning

confidence: 90%

Immediate and long-term electrophysiological biomarkers of antidepressant-like behavioral effects after subanesthetic ketamine and medial prefrontal cortex deep brain stimulation treatment

Bergosh,

Medvidovic,

Zepeda

et al. 2024

Front. Neurosci.

View full text Add to dashboard Cite

IntroductionBoth ketamine (KET) and medial prefrontal cortex (mPFC) deep brain stimulation (DBS) are emerging therapies for treatment-resistant depression, yet our understanding of their electrophysiological mechanisms and biomarkers is incomplete. This study investigates aperiodic and periodic spectral parameters, and the signal complexity measure sample entropy, within mPFC local field potentials (LFP) in a chronic corticosterone (CORT) depression model after ketamine and/or mPFC DBS.MethodsMale rats were intraperitoneally administered CORT or vehicle for 21 days. Over the last 7 days, animals receiving CORT were treated with mPFC DBS, KET, both, or neither; then tested across an array of behavioral tasks for 9 days.ResultsWe found that the depression-like behavioral and weight effects of CORT correlated with a decrease in aperiodic-adjusted theta power (5–10 Hz) and an increase in sample entropy during the administration phase, and an increase in theta peak frequency and a decrease in the aperiodic exponent once the depression-like phenotype had been induced. The remission-like behavioral effects of ketamine alone correlated with a post-treatment increase in the offset and exponent, and decrease in sample entropy, both immediately and up to eight days post-treatment. The remission-like behavioral effects of mPFC DBS alone correlated with an immediate decrease in sample entropy, an immediate and sustained increase in low gamma (20–50 Hz) peak width and aperiodic offset, and sustained improvements in cognitive function. Failure to fully induce remission-like behavior in the combinatorial treatment group correlated with a failure to suppress an increase in sample entropy immediately after treatment.ConclusionOur findings therefore support the potential of periodic theta parameters as biomarkers of depression-severity; and periodic low gamma parameters and cognitive measures as biomarkers of mPFC DBS treatment efficacy. They also support sample entropy and the aperiodic spectral parameters as potential cross-modal biomarkers of depression severity and the therapeutic efficacy of mPFC DBS and/or ketamine. Study of these biomarkers is important as objective measures of disease severity and predictive measures of therapeutic efficacy can be used to personalize care and promote the translatability of research across studies, modalities, and species.

show abstract

Section: 13mentioning

confidence: 90%

Immediate and long-term electrophysiological biomarkers of antidepressant-like behavioral effects after subanesthetic ketamine and medial prefrontal cortex deep brain stimulation treatment

Bergosh,

Medvidovic,

Zepeda

et al. 2024

Front. Neurosci.

View full text Add to dashboard Cite

show abstract

A Habenula Neural Biomarker Simultaneously Tracks Weekly and Daily Symptom Variations during Deep Brain Stimulation Therapy for Depression

Liu,

Qi,

et al. 2024

Preprint

View full text Add to dashboard Cite

Deep brain stimulation (DBS) targeting the lateral habenula (LHb) is a promising therapy for treatment-resistant depression (TRD) but its clinical effect has been variable, which can be improved by adaptive DBS (aDBS) guided by a neural biomarker of depression symptoms. A clinically-viable neural biomarker is desired to classify depression symptom states, track both slow and fast symptom variations during the treatment, and respond to DBS parameter alterations, which is currently lacking. Here, we conducted a study on one TRD patient who achieved remission following a 41-week LHb DBS treatment, during which we assessed slow symptom variations using weekly clinical ratings and fast variations using daily self-reports. We recorded daily LHb local field potentials (LFP) concurrently with the reports during the entire treatment process. We then used machine learning methods to identify a personalized depression neural biomarker from spectral and temporal LFP features. The identified neural biomarker classified high and low depression symptom severity states with a cross-validated accuracy of 0.97. It further simultaneously tracked both weekly (slow) and daily (fast) depression symptom variation dynamics, achieving test data explained variance of 0.74 and 0.63, respectively. It finally responded to DBS frequency alterations. Our results hold promise to identify clinically-viable neural biomarkers to facilitate future aDBS for treating TRD.

show abstract

Depresión Resistente y Neurocirugía: Estado del Arte de la Estimulación Cerebral Profunda del Área Subgenual (Área 25)

Villamil,

Mandolesi,

Catena Baudo

et al. 2024

NeuroTarget

View full text Add to dashboard Cite

Introducción y Objetivo. La depresión resistente al tratamiento (DRT) es una condición debilitante que no responde a los tratamientos antidepresivos convencionales. La estimulación cerebral profunda (ECP) del área subgenual (Cg25) ha emergido como una opción prometedora para estos pacientes. Este estudio tiene como objetivo evaluar la seguridad, eficacia y mecanismos subyacentes de la ECP en la región Cg25 para tratar la DRT.Método. Se realizó una revisión sistemática de la literatura utilizando PubMed, Scopus y Cochrane Library. Se incluyeron estudios y revisiones sobre ECP para DRT publicados entre 2005 y 2024. Se extrajeron y analizaron datos sobre mecanismos de acción, eficacia clínica, efectos adversos y factores predictivos de éxito.Resultados. Se incluyeron un total de 14 estudios abiertos y tres ensayos controlados aleatorios (ECA) que investigaban la ECP del área subgenual. La tasa de respuesta general fue del 56% y la tasa de remisión del 35%. La variabilidad en los resultados se relacionó con diferentes parámetros de estimulación y la cronicidad de la enfermedad. Los estudios resaltaron la importancia de dirigir la estimulación hacia tractos específicos de sustancia blanca para optimizar los resultados clínicos. El uso de tractografía probabilística para mapear el "prototipo de conectoma" óptimo ha mostrado mejoras prometedoras en las tasas de respuesta y remisión.Conclusiones. La ECP del área subgenual muestra potencial como tratamiento para la DRT, especialmente cuando se utilizan enfoques de orientación basados en conectomas. Se necesita más investigación para optimizar los parámetros de estimulación y validar biomarcadores predictivos de respuesta.

show abstract

Effects of deep brain stimulation on cognitive functioning in treatment-resistant depression: a systematic review and meta-analysis

Cited by 3 publications

References 56 publications

Immediate and long-term electrophysiological biomarkers of antidepressant-like behavioral effects after subanesthetic ketamine and medial prefrontal cortex deep brain stimulation treatment

Immediate and long-term electrophysiological biomarkers of antidepressant-like behavioral effects after subanesthetic ketamine and medial prefrontal cortex deep brain stimulation treatment

A Habenula Neural Biomarker Simultaneously Tracks Weekly and Daily Symptom Variations during Deep Brain Stimulation Therapy for Depression

Depresión Resistente y Neurocirugía: Estado del Arte de la Estimulación Cerebral Profunda del Área Subgenual (Área 25)

Contact Info

Product

Resources

About